0001004878-16-000565.txt : 20161215 0001004878-16-000565.hdr.sgml : 20161215 20161215164134 ACCESSION NUMBER: 0001004878-16-000565 CONFORMED SUBMISSION TYPE: NT 10-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20160930 FILED AS OF DATE: 20161215 DATE AS OF CHANGE: 20161215 EFFECTIVENESS DATE: 20161215 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CEL SCI CORP CENTRAL INDEX KEY: 0000725363 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 840916344 STATE OF INCORPORATION: CO FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: NT 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11889 FILM NUMBER: 162054127 BUSINESS ADDRESS: STREET 1: 8229 BOONE BLVD . STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 BUSINESS PHONE: 7035069460 MAIL ADDRESS: STREET 1: 8229 BOONE BLVD. STREET 2: SUITE 802 CITY: VIENNA STATE: VA ZIP: 22182 FORMER COMPANY: FORMER CONFORMED NAME: INTERLEUKIN 2 INC DATE OF NAME CHANGE: 19880317 NT 10-K 1 sept201610k12b12-16.txt SEPT 2016 10-K 12B-25 U.S. SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SEC File Number 001-11889 CUSIP Number 150837508 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): [X] Form 10-K [ ] Form 20-F [ ] Form 11-K [ ] Form 10-Q [ ] Form 10-D [ ] Form N-SAR For Period Ended: September 30, 2016. [ ] Transition Report on Form 10-K [ ] Transition Report on Form 10-Q For the Transition Period Ended: ________________________________ --------------------------------- Nothing in this Form shall be construed to imply that the Commission has verified any information contained herein. --------------------------------- Part I - Registrant Information --------------------------------- Full Name of Registrant: CEL-SCI CORPORATION Former Name if Applicable: N/A Address of Principal Executive Office (Street and Number) 8229 Boone Blvd. #802 City, State and Zip Code Vienna, VA 22182 --------------------------------- Part II - Rules 12b-25(b) and (c) --------------------------------- If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate) [X] (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; [X] (b) The subject annual report, semi-annual report, or transition report or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form l0-Q or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and [ ] (c) The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. --------------------------------- Part III - Narrative --------------------------------- State below in reasonable detail the reasons why the Form 10-K, 20-F, 11-K, 10-Q, or N-SAR, or the transition report or portion thereof could not be filed within the prescribed time period. On December 14, 2016 the Company filed its Annual Report on Form 10-K for the year ended September 30, 2016. However, at the time the 10-K report was filed, the Company did not have sufficient time to complete Exhibit 101 (Interactive Data Files) to the report. The amended 10-K report, with Exhibit 101, will be filed on December 15, 2016. --------------------------------- Part IV - Other Information --------------------------------- (1) Name and telephone number of person to contact in regard to this notification William T. Hart (303) 839-0061 ----------------- ----- ---------------- (Name) (Area Code) (Telephone Number) (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding l2 months (or for such shorter period that the registrant was required to file such reports) been filed? If answer is no, identify report(s). [X] Yes [ ] No (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? [ ] Yes [X] No If so: attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made. CEL--SCI CORPORATION ------------------------------ (Name of Registrant as specified in charter) has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized. CEL-SCI CORPORATION Date: December 15, 2016 By: /s/ Patricia B. Prichep ---------------------------- Patricia B. Prichep enior Vice President of Operations ATTENTION Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).